AR and prostate carcinoma: Indeed, genomic alterations in multiple PI3K pathway genes besides PTEN have been identified in advanced prostate cancer [28, 64], and cross‐talk between the PI3K‐AKT–mTOR pathway and other pathways including AR signaling [65], Wnt [66], and Ras/MAPK [67, 68] pathways can converge on mTOR pathway activation in the absence of PI3K pathway genomic alterations altogether.